Rammer E, Friedrich F
Abteilung für Gynäkologic und Geburtshilfe, Allgemeines öffentliches Krankenhaus Horn.
Wien Klin Wochenschr. 1996;108(6):180-3.
In this randomized double-blind clinical study the efficacy of an enzyme preparation (Wobenzym) was compared with hormone therapy (Lynestrenol) in 29 women with mastopathy. There was a significantly greater decrease in number of hardenings of the mammary gland after 2 months of enzyme therapy than Lynestrenol therapy: improvement in the former group was 100%, in the latter group 78.6%. No significant difference was observed regarding the numbers of lumps, or number and size of cysts, sensitivity to touch, feeling of tension, spontaneous pain, and pain on pressure. The efficacy of both medicines is valued as good. Wobenzym therapy was tolerated very well. No side effects appeared at all. Enzyme therapy is an alternative, low-risk therapy for the management of mastopathy, which does not interfere with the already upset hormonal balance of the patients.
在这项随机双盲临床研究中，对29名乳腺病女性患者比较了一种酶制剂（沃贝酶）与激素疗法（炔雌醇）的疗效。酶疗法治疗2个月后，乳腺硬结数量的减少明显大于炔雌醇疗法：前一组的改善率为100%，后一组为78.6%。在肿块数量、囊肿数量和大小、触痛、紧绷感、自发疼痛以及压痛方面未观察到显著差异。两种药物的疗效均被评价为良好。沃贝酶疗法耐受性非常好，完全没有出现副作用。酶疗法是治疗乳腺病的一种替代的、低风险疗法，不会干扰患者本已紊乱的激素平衡。
